Collaboration announced between Intarcia, Numab for antibody development

A strategic collaboration has been announced between Intarcia Therapeutics, Inc., and Numab AG focusing on the development of once- or twice-yearly mono-specific and multi-specific antibodies, according to a press release.

The antibodies will be used to address diabetes, obesity and autoimmune diseases.

“We believe the unique characteristics of Numab’s antibody technology fit perfectly with our disruptive platform technologies, which have the potential to eliminate life-long injections and produce best-in-disease once- or twice-yearly medicines,” Kurt Graves, chairman, president and CRO of Intarcia Therapeutics, said in the release. “Now is the time, as we finish our phase 3 program for ITCA 650 in type 2 diabetes, to take this important strategic step to enhance and expand our pipeline. This collaboration reinforces Intarcia’s ongoing priority to develop game-changing therapeutics that address major unmet medical needs, such as suboptimal efficacy, as well as poor compliance and adherence.”

Numab will be eligible to receive milestone payments as well as royalties from sales resulting from the collaboration. The collaboration can be extended beyond the initial assets and targets as an option by Intarcia. Development, manufacturing and commercialization of all products resulting from the collaboration will be under the responsibility of Intarcia.

“This collaboration triggers the development of a new generation of medications that addresses the notorious shortcomings of conventional antibody therapeutics,” David Urech, PhD, CSO and co-CEO of Numab AG, said in the release. “It reflects Numab’s ambition to partner with companies that share our dedication for true innovation.”

A strategic collaboration has been announced between Intarcia Therapeutics, Inc., and Numab AG focusing on the development of once- or twice-yearly mono-specific and multi-specific antibodies, according to a press release.

The antibodies will be used to address diabetes, obesity and autoimmune diseases.

“We believe the unique characteristics of Numab’s antibody technology fit perfectly with our disruptive platform technologies, which have the potential to eliminate life-long injections and produce best-in-disease once- or twice-yearly medicines,” Kurt Graves, chairman, president and CRO of Intarcia Therapeutics, said in the release. “Now is the time, as we finish our phase 3 program for ITCA 650 in type 2 diabetes, to take this important strategic step to enhance and expand our pipeline. This collaboration reinforces Intarcia’s ongoing priority to develop game-changing therapeutics that address major unmet medical needs, such as suboptimal efficacy, as well as poor compliance and adherence.”

Numab will be eligible to receive milestone payments as well as royalties from sales resulting from the collaboration. The collaboration can be extended beyond the initial assets and targets as an option by Intarcia. Development, manufacturing and commercialization of all products resulting from the collaboration will be under the responsibility of Intarcia.

“This collaboration triggers the development of a new generation of medications that addresses the notorious shortcomings of conventional antibody therapeutics,” David Urech, PhD, CSO and co-CEO of Numab AG, said in the release. “It reflects Numab’s ambition to partner with companies that share our dedication for true innovation.”